About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing next generation, iTANK-armed, cell and gene therapies based on CAR T-cells and oncolytic viruses.

Elicera Therapeutics in brief

The company has developed the patented genetic engineering method iTANK, which makes it possible to develop completely new treatments and refine existing CAR T-cell therapies against aggressive and recurrent cancers. Elicera Therapeutics thus has access to a well-defined and extensive market. The company's CAR T-cell therapies have shown in preclinical studies a potent effect against solid tumors, which are known to be difficult to treat and constitute the majority of cancers. The company addresses an international market worth billions in cell therapy development by offering non-exclusive out-licensing of iTANK to players in the pharmaceutical industry. In parallel, Elicera Therapeutics is running four internal immunotherapy development projects (2 CAR T-cells programs and 2 oncolytic virus programs), all of which have the potential to generate significant revenues in the form of exclusive licensing agreements.